BG105302A - Means for improving cognition - Google Patents
Means for improving cognitionInfo
- Publication number
- BG105302A BG105302A BG105302A BG10530201A BG105302A BG 105302 A BG105302 A BG 105302A BG 105302 A BG105302 A BG 105302A BG 10530201 A BG10530201 A BG 10530201A BG 105302 A BG105302 A BG 105302A
- Authority
- BG
- Bulgaria
- Prior art keywords
- improving cognition
- acetylcholinesterase
- alzheimer
- inhibitor
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98203454 | 1998-10-16 | ||
PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
Publication Number | Publication Date |
---|---|
BG105302A true BG105302A (en) | 2001-11-30 |
Family
ID=8234219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG105302A BG105302A (en) | 1998-10-16 | 2001-03-01 | Means for improving cognition |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1121131A2 (ko) |
JP (1) | JP2002527469A (ko) |
KR (1) | KR20010072878A (ko) |
CN (1) | CN1367697A (ko) |
AU (1) | AU6472799A (ko) |
BG (1) | BG105302A (ko) |
BR (1) | BR9914419A (ko) |
CA (1) | CA2345767A1 (ko) |
EE (1) | EE200100136A (ko) |
HK (1) | HK1039745A1 (ko) |
HR (1) | HRP20010262A2 (ko) |
HU (1) | HUP0103781A3 (ko) |
ID (1) | ID28441A (ko) |
IL (1) | IL142588A0 (ko) |
NO (1) | NO20011403L (ko) |
PL (1) | PL348107A1 (ko) |
SK (1) | SK4592001A3 (ko) |
TR (1) | TR200101082T2 (ko) |
WO (1) | WO2000023057A2 (ko) |
ZA (1) | ZA200103081B (ko) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
JP5067998B2 (ja) | 2001-10-30 | 2012-11-07 | ノバルティス アーゲー | イロペリドンおよび星形ポリマーのデポー製剤 |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
EP1824848A1 (en) * | 2004-12-10 | 2007-08-29 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
EP1776089A2 (en) * | 2003-12-31 | 2007-04-25 | Actavis Group hf | Donepezil formulations |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
NZ579310A (en) | 2007-03-01 | 2012-03-30 | Probiodrug Ag | Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
WO1999007378A1 (en) * | 1997-08-11 | 1999-02-18 | THE UNIVERSITY OF SOUTH FLORIDA A Corporation of the State of Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
AU765603C (en) * | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
-
1999
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Application Discontinuation
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/no not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PL348107A1 (en) | 2002-05-06 |
AU6472799A (en) | 2000-05-08 |
CN1367697A (zh) | 2002-09-04 |
NO20011403D0 (no) | 2001-03-20 |
EE200100136A (et) | 2002-06-17 |
ZA200103081B (en) | 2002-07-12 |
HK1039745A1 (zh) | 2002-05-10 |
TR200101082T2 (tr) | 2001-09-21 |
HUP0103781A2 (hu) | 2002-03-28 |
WO2000023057A2 (en) | 2000-04-27 |
EP1121131A2 (en) | 2001-08-08 |
ID28441A (id) | 2001-05-24 |
WO2000023057A3 (en) | 2000-07-27 |
CA2345767A1 (en) | 2000-04-27 |
NO20011403L (no) | 2001-03-20 |
BR9914419A (pt) | 2001-06-26 |
JP2002527469A (ja) | 2002-08-27 |
IL142588A0 (en) | 2002-03-10 |
KR20010072878A (ko) | 2001-07-31 |
HRP20010262A2 (en) | 2002-06-30 |
HUP0103781A3 (en) | 2003-09-29 |
SK4592001A3 (en) | 2001-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG105302A (en) | Means for improving cognition | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
SI1509232T1 (sl) | Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni | |
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
BR0008059A (pt) | Composições de valdecoxib | |
HK1029043A1 (en) | Remedy for neurodegenerative diseases. | |
NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
IL119989A0 (en) | Pharmaceutical compositions for oral treatment of multiple sclerosis | |
HU9603042D0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration | |
AU2002307049A1 (en) | Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia | |
ATE240115T1 (de) | Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose | |
BG105256A (en) | Muscarinic agonists and antagonists | |
IL149134A0 (en) | Pharmaceutical compositions containing tofisopam | |
IL124091A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it | |
RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
IL159241A0 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
MX9707642A (es) | Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos. | |
AU4568400A (en) | Sphingomyelinase inhibitor | |
RS60604A (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
GEP20043377B (en) | Pharmaceutical Complex | |
IL129267A (en) | Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence |